decisionhealth Newsletters, Part B News - 2002 Issue 5 (May)
Carriers should pay for drug used in AK treatments, CMS says
Subscribe or sign in to view the full article.
Article Overview
This article discusses a CMS letter addressing Medicare carrier payment policies for actinic keratosis treatment, including the relationship between photodynamic therapy and an associated drug. It is useful for physicians, coders, billing staff, and compliance teams who handle dermatology claims and Medicare coverage questions. The article also places the guidance in the context of CMS coverage policy and carrier practices.
Why This Topic Matters
The article matters because it clarifies a Medicare coverage issue affecting billing for actinic keratosis therapy and helps readers understand the broader coverage framework behind treatment-related claims.
What You Will Learn
- How CMS framed Medicare coverage for actinic keratosis treatment
- Why the article discusses carrier payment practices for a therapy-related drug
- What broad treatment categories CMS identified for actinic keratosis care
- How the coverage discussion relates to Medicare policy and carrier guidance
Who Should Read This
- Physicians
- Medical coders
- Billing staff
- Practice managers
- Compliance professionals
- Dermatology practices
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com